Evidence map›Paper›PMID 29760016›Full record

ArticleCirculation research2018

Diabetes-Induced Cardiomyocyte Passive Stiffening Is Caused by Impaired Insulin-Dependent Titin Modification and Can Be Modulated by Neuregulin-1.

Anna-Eliane Hopf, Christian Andresen, Sebastian Kötter, Małgorzata Isić, Kamila Ulrich, Senem Sahin, Sabine Bongardt, Wilhelm Röll, Felicitas Drove, Nina Scheerer and 5 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Circulation research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Anna-Eliane HopfFrom the Medical Faculty, Department of Cardiovascular Physiology, Heinrich-Heine-University, Düsseldorf, Germany (A.-E.H., C.A., S.K., M.I., S.S., S.B., M.K.).
Christian AndresenFrom the Medical Faculty, Department of Cardiovascular Physiology, Heinrich-Heine-University, Düsseldorf, Germany (A.-E.H., C.A., S.K., M.I., S.S., S.B., M.K.).
Sebastian KötterFrom the Medical Faculty, Department of Cardiovascular Physiology, Heinrich-Heine-University, Düsseldorf, Germany (A.-E.H., C.A., S.K., M.I., S.S., S.B., M.K.).
Małgorzata IsićFrom the Medical Faculty, Department of Cardiovascular Physiology, Heinrich-Heine-University, Düsseldorf, Germany (A.-E.H., C.A., S.K., M.I., S.S., S.B., M.K.).
Kamila UlrichDepartment of Systems Physiology, Ruhr-University Bochum, Germany (K.U., N.H.).
Senem SahinFrom the Medical Faculty, Department of Cardiovascular Physiology, Heinrich-Heine-University, Düsseldorf, Germany (A.-E.H., C.A., S.K., M.I., S.S., S.B., M.K.).
Sabine BongardtFrom the Medical Faculty, Department of Cardiovascular Physiology, Heinrich-Heine-University, Düsseldorf, Germany (A.-E.H., C.A., S.K., M.I., S.S., S.B., M.K.).
Wilhelm RöllDepartment of Cardiovascular Surgery, University Clinic Bonn, Germany (W.R.).
Felicitas DroveBayer AG, Drug Discovery, Pharmaceuticals, Wuppertal, Germany (F.D., N.S.).
Nina ScheererBayer AG, Drug Discovery, Pharmaceuticals, Wuppertal, Germany (F.D., N.S.).
Leni VandekerckhoveDepartment of Pharmaceutical Sciences, Laboratory of Physiopharmacology, Campus Drie Eiken, University of Antwerp, Belgium (L.V., G.W.D.).
Gilles W De KeulenaerDepartment of Pharmaceutical Sciences, Laboratory of Physiopharmacology, Campus Drie Eiken, University of Antwerp, Belgium (L.V., G.W.D.).
Nazha HamdaniDepartment of Systems Physiology, Ruhr-University Bochum, Germany (K.U., N.H.).
Wolfgang A LinkeInstitute of Physiology II, University of Munster, Germany (W.A.L.).
Martina KrügerFrom the Medical Faculty, Department of Cardiovascular Physiology, Heinrich-Heine-University, Düsseldorf, Germany (A.-E.H., C.A., S.K., M.I., S.S., S.B., M.K.) martina.krueger@uni-duesseldorf.de.
Heinrich Heine University Düsseldorf · DERuhr University Bochum · DEBayer (Germany) · DEUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleIncreased titin-dependent cardiomyocyte tension is a hallmark of heart failure with preserved ejection fraction associated with type-2 diabetes mellitus. However, the insulin-related signaling pathways that modify titin-based cardiomyocyte tension, thereby contributing to modulation of diastolic function, are largely unknown.

objectiveWe aimed to determine how impaired insulin signaling affects titin expression and phosphorylation and thus increases passive cardiomyocyte tension, and whether metformin or neuregulin-1 (NRG-1) can correct disturbed titin modifications and increased titin-based stiffness. METHODS AND

resultsWe used cardiac biopsies from human diabetic (n=23) and nondiabetic patients (n=19), cultured rat cardiomyocytes, left ventricular tissue from apolipoprotein E-deficient mice with streptozotocin-induced diabetes mellitus (n=12-22), and ZSF1 (obese diabetic Zucker fatty/spontaneously hypertensive heart failure F1 hybrid) rats (n=5-6) and analyzed insulin-dependent signaling pathways that modulate titin phosphorylation. Titin-based passive tension was measured using permeabilized cardiomyocytes. In human diabetic hearts, we detected titin hypophosphorylation at S4099 and hyperphosphorylation at S11878, suggesting altered activity of protein kinases; cardiomyocyte passive tension was significantly increased. When applied to cultured cardiomyocytes, insulin and metformin increased titin phosphorylation at S4010, S4099, and S11878 via enhanced ERK1/2 (extracellular signal regulated kinase 1/2) and PKCα (protein kinase Cα) activity; NRG-1 application enhanced ERK1/2 activity but reduced PKCα activity. In apolipoprotein E-deficient mice, chronic treatment of streptozotocin-induced diabetes mellitus with NRG-1 corrected titin phosphorylation via increased PKG (protein kinase G) and ERK1/2 activity and reduced PKCα activity, which reversed the diabetes mellitus-associated changes in titin-based passive tension. Acute application of NRG-1 to obese ZSF1 rats with type-2 diabetes mellitus reduced end-diastolic pressure.

conclusionsMechanistically, we found that impaired cGMP-PKG signaling and elevated PKCα activity are key modulators of titin-based cardiomyocyte stiffening in diabetic hearts. We conclude that by restoring normal kinase activities of PKG, ERK1/2, and PKCα, and by reducing cardiomyocyte passive tension, chronic NRG-1 application is a promising approach to modulate titin properties in heart failure with preserved ejection fraction associated with type-2 diabetes mellitus.

Indexed as

Protein Processing, Post-TranslationalSignal TransductionAnimalsCells, CulturedConnectinCyclic GMPCyclic GMP-Dependent Protein KinasesDiabetic CardiomyopathiesHumansHypoglycemic AgentsInsulinMetforminMiceMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Myocytes, CardiacConnectinCyclic GMPCyclic GMP-Dependent Protein KinasesHypoglycemic AgentsInsulinMetforminMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Neuregulin-1Protein Kinase C-alphaconnectindiabetes mellitus, type 2insulinmetforminphosphorylation

Identifiers

PMID29760016
OpenAlexW2802040201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.